RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Eiger BioPharmaceuticals Stock

Eiger BioPharmaceuticals Liabilities 2024

Eiger BioPharmaceuticals Liabilities

53.28 M USD

Ticker

EIGR

ISIN

US28249U1051

WKN

A2AF9X

In 2024, Eiger BioPharmaceuticals's total liabilities amounted to 53.28 M USD, a -17.77% difference from the 64.8 M USD total liabilities in the previous year.

Eiger BioPharmaceuticals Aktienanalyse

What does Eiger BioPharmaceuticals do?

Eiger BioPharmaceuticals Inc is a US biopharmaceutical company that specializes in developing therapeutics for rare and serious diseases. It was founded in 2008 and is headquartered in Palo Alto, California. The company's history is closely tied to the discovery of hepatitis C medications, and their business model focuses on developing antiviral therapies for rare and severe diseases. They have multiple divisions dedicated to different therapeutic areas, including hepatitis C, hepatitis D, fibrosis, and lysosomal storage disorders. They currently offer several products, including Zokinvy for chronic hepatitis C infection and Lambda for hepatitis D. They have also formed strategic partnerships with other pharmaceutical companies to support the development and commercialization of their products. Overall, Eiger BioPharmaceuticals Inc is known for its innovative approach and commitment to improving treatment options for patients with serious medical needs. Eiger BioPharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Eiger BioPharmaceuticals's Liabilities

Eiger BioPharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Eiger BioPharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Eiger BioPharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Eiger BioPharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Eiger BioPharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Eiger BioPharmaceuticals stock

What is the level of liabilities of Eiger BioPharmaceuticals this year?

Eiger BioPharmaceuticals has a debt balance of 53.28 M USD this year.

What were the liabilities of Eiger BioPharmaceuticals compared to the previous year?

The liabilities of Eiger BioPharmaceuticals have increased by -17.77% dropped compared to the previous year.

What are the consequences of high debt for investors of Eiger BioPharmaceuticals?

High liabilities can pose a risk for investors of Eiger BioPharmaceuticals, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Eiger BioPharmaceuticals?

Low liabilities mean that Eiger BioPharmaceuticals has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Eiger BioPharmaceuticals affect the company?

An increase in liabilities of Eiger BioPharmaceuticals can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Eiger BioPharmaceuticals affect the company?

A decrease in the liabilities of Eiger BioPharmaceuticals can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Eiger BioPharmaceuticals?

Some factors that can influence the liabilities of Eiger BioPharmaceuticals include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Eiger BioPharmaceuticals so important for investors?

The liabilities of Eiger BioPharmaceuticals are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Eiger BioPharmaceuticals take to modify the liabilities?

To change its liabilities, Eiger BioPharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Eiger BioPharmaceuticals pay?

Over the past 12 months, Eiger BioPharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Eiger BioPharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Eiger BioPharmaceuticals?

The current dividend yield of Eiger BioPharmaceuticals is .

When does Eiger BioPharmaceuticals pay dividends?

Eiger BioPharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Eiger BioPharmaceuticals?

Eiger BioPharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Eiger BioPharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Eiger BioPharmaceuticals located?

Eiger BioPharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Eiger BioPharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Eiger BioPharmaceuticals from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Eiger BioPharmaceuticals pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Eiger BioPharmaceuticals in the year 2023?

In the year 2023, Eiger BioPharmaceuticals distributed 0 USD as dividends.

In which currency does Eiger BioPharmaceuticals pay out the dividend?

The dividends of Eiger BioPharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Eiger BioPharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Eiger BioPharmaceuticals

Our stock analysis for Eiger BioPharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Eiger BioPharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.